Literature DB >> 9850354

Hyperthyroidism influences ultrasound bone measurement on the Os calcis.

C Gómez Acotto1, A M Schott, D Hans, H Niepomniszcze, C A Mautalen, P J Meunier.   

Abstract

The objective of our study was to compare bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) parameters in women with hyperthyroidism and controls. In this cross-sectional study, QUS parameters and BMD values observed in untreated hyperthyroid patients were compared with data obtained from age-matched controls. Twenty-four women with Graves' disease were studied. Eight patients were postmenopausal. All patients had evidence of thyrotoxicosis as indicated by a raised total serum thyroxine and a suppressed serum thyroid stimulating hormone. BMD of the hip, lumbar spine and whole body, and body composition, were measured by DXA. Ultrasound evaluation on the os calcis was performed with an Achilles device. All measurements were performed before antithyroid therapy. The QUS parameters of BUA, SOS and Stiffness were significantly lower in hyperthyroid patients than in controls. Similar results were observed for the BMD of lumbar spine, femoral neck and total skeleton. Lean tissue and fat mass were also significantly decreased in hyperthyroid patients. In conclusion, these findings suggest that hyperthyroidism affects cortical and trabecular bone equally, as well as bone quality. QUS measurements may be helpful for assessing, using a simple and non-irradiating method, the bone effects of thyrotoxicosis.

Entities:  

Mesh:

Year:  1998        PMID: 9850354     DOI: 10.1007/s001980050091

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  7 in total

Review 1.  Ultrasound of the skeleton: review of its clinical applications and pitfalls.

Authors:  R D Danese; A A Licata
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.

Authors:  Takafumi Majima; Yasato Komatsu; Kentaro Doi; Chieko Takagi; Michika Shigemoto; Atsushi Fukao; Takeshi Morimoto; Jerry Corners; Kazuwa Nakao
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease.

Authors:  T Majima; Y Komatsu; K Doi; C Takagi; M Shigemoto; A Fukao; T Morimoto; J Corners; K Nakao
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

4.  Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts.

Authors:  E Tsourdi; H Wallaschofski; M Rauner; M Nauck; M Pietzner; R Rettig; T Ittermann; H Völzke; U Völker; L C Hofbauer; A Hannemann
Journal:  Osteoporos Int       Date:  2015-08-12       Impact factor: 4.507

5.  Levothyroxine dose and risk of fractures in older adults: nested case-control study.

Authors:  Marci R Turner; Ximena Camacho; Hadas D Fischer; Peter C Austin; Geoff M Anderson; Paula A Rochon; Lorraine L Lipscombe
Journal:  BMJ       Date:  2011-04-28

6.  Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease.

Authors:  Monica A Ercolano; Monica L Drnovsek; Maria C Silva Croome; Monica Moos; Ana M Fuentes; Fanny Viale; Ulla Feldt-Rasmussen; Alicia T Gauna
Journal:  Thyroid Res       Date:  2013-09-11

7.  Changes in bone mineral density and trabecular bone score in Graves' disease patients after anti-thyroid therapy.

Authors:  So Young Ock; Yoon-Sok Chung; Yong Jun Choi
Journal:  Osteoporos Sarcopenia       Date:  2016-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.